^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tevimbra (tislelizumab-jsgr)

    i
    Other names: VDT482, BGBA317, VDT 482, VDT-482, BGB-A317, BGB A317
    Company:
    BeOne Medicines
    Drug class:
    PD1 inhibitor
    Related drugs:
    1d
    Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P3, N=172, Not yet recruiting, Asan Medical Center | Initiation date: Jun 2025 --> Jan 2026
    Trial initiation date • Circulating tumor DNA
    |
    carboplatin • paclitaxel • Tevimbra (tislelizumab-jsgr)
    2d
    Disitamab vedotin (RC48-ADC) combined with immunotherapy as neoadjuvant therapy for localized muscle-invasive bladder cancer: a multicenter real-world study. (PubMed, NPJ Precis Oncol)
    Neoadjuvant cisplatin-based combination chemotherapy or perioperative durvalumab with neoadjuvant gemcitabine-cisplatin has been the primary treatment for localized muscle-invasive bladder cancer (MIBC)...Twenty-five patients (cT2-4aN0-2M0) received at least four cycles of RC48 (2.0 mg/kg, Q2W or Q3W) with toripalimab, tislelizumab, or pembrolizumab, followed by radical cystectomy...Treatment-related adverse events were manageable. These findings suggest that RC48 combined with PD-1 inhibitors is a promising neoadjuvant strategy for localized MIBC and warrants further validation in biomarker-selected populations.
    Journal • Real-world evidence • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression
    |
    Keytruda (pembrolizumab) • Imfinzi (durvalumab) • gemcitabine • Loqtorzi (toripalimab-tpzi) • Tevimbra (tislelizumab-jsgr) • Aidixi (disitamab vedotin)
    3d
    Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma (clinicaltrials.gov)
    P2, N=20, Recruiting, The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Focus V (anlotinib) • Tevimbra (tislelizumab-jsgr)
    4d
    Phase 1b/2 Study of Zanidatamab in Combination with Tislelizumab and Chemotherapy in First-Line HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma. (PubMed, Clin Cancer Res)
    Zanidatamab, in combination with tislelizumab and CAPOX, demonstrated clinically meaningful antitumor activity with a manageable safety profile as first-line therapy for patients with HER2+ GC/GEJC. These results support further development of zanidatamab and tislelizumab with chemotherapy in this patient population in the ongoing phase 3 HERIZON-GEA-01 trial (NCT05152147).
    P1/2 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • Ziihera (zanidatamab-hrii)
    4d
    Tislelizumab and hypofractionated radiotherapy plus nab-paclitaxel/gemcitabine as conversion therapy for BRPC/LAPC: A Phase II trial with dynamic biomarker monitoring. (PubMed, Clin Cancer Res)
    The THAG regimen as preoperative therapy showed encouraging clinical activity with a manageable safety profile. Dynamic biomarker findings reveal potential for guiding precision treatment strategies with THAG.
    P2 data • Journal • PD(L)-1 Biomarker
    |
    IL6 (Interleukin 6)
    |
    gemcitabine • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel
    6d
    LBL-007-CN-004: A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors (clinicaltrials.gov)
    P1/2, N=490, Recruiting, Nanjing Leads Biolabs Co.,Ltd | Trial completion date: Dec 2025 --> Jul 2026 | Trial primary completion date: Oct 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    cisplatin • gemcitabine • docetaxel • Tevimbra (tislelizumab-jsgr) • alcestobart (LBL-007)
    6d
    Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=308, Recruiting, BeOne Medicines | N=227 --> 308
    Enrollment change • First-in-human
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr)
    6d
    Tislelizumab Combined With XELOX as Neoadjuvant Therapy for G/GEJ Adenocarcinoma (clinicaltrials.gov)
    P2, N=28, Completed, Xijing Hospital | Recruiting --> Completed | Trial completion date: Jul 2026 --> Oct 2025
    Trial completion • Trial completion date
    |
    Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin
    8d
    A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma. (clinicaltrials.gov)
    P2/3, N=737, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
    New P2/3 trial • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    EGFR expression
    |
    cisplatin • paclitaxel • 5-fluorouracil • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • Enshuxing (enlonstobart) • SYS6010
    8d
    Open-label, single-arm, phase 2 trial to investigate the efficacy of sitravatinib plus tislelizumab combination as a second-line treatment for advanced biliary tract cancer. (PubMed, J Hepatol)
    Sitravatinib/tislelizumab combination as second-line treatment in patients with advanced BTC demonstrated meaningful efficacy and an acceptable safety profile. Patient selection using HRD biomarkers may be a promising strategy in this setting.
    P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HRD (Homologous Recombination Deficiency)
    |
    HRD
    |
    Tevimbra (tislelizumab-jsgr) • sitravatinib (MGCD516)
    9d
    Neoadjuvant tislelizumab with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma. (PubMed, Int J Surg)
    Neoadjuvant tislelizumab with chemoradiotherapy shows promising efficacy and a manageable safety profile in ESCC, with key immunological signatures, such as memory T cell responses, emerging as strong predictors of long-term clinical benefit.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    Tevimbra (tislelizumab-jsgr)
    9d
    Tislelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo Metastatic Nasopharyngeal Carcinoma: A Prospective, Phase II Trial (clinicaltrials.gov)
    P=N/A, N=32, Active, not recruiting, Chongqing University Cancer Hospital
    New trial
    |
    cisplatin • Tevimbra (tislelizumab-jsgr)